Alzeimer’s Decline Detection
A decision support monitoring tool for physicians to detect in a timely manner functional decline in their AD patients.
Inventors
Dr. Amir Glik, Rabin Medical Center
Prof. Felix Benninger, Rabin Medical Center
Contact info
Avital Pritz, Director of Medical Devices and Digital Health
For further information please contact:
avital@mor-research.comA decision support monitoring tool for physicians to detect in a timely manner functional decline in their AD patients.
It is based on an algorithm which analyzes EEG records and can demonstrate whether the subject improves or deteriorates instantly.
The reference for each subject is to self and not to the population (personalized medicine).
The algorithm was tested on ~700 EEG readings and demonstrated correlation between the cognitive performance and the microstates characteristics.
The Opportunity
The global Alzheimer’s therapeutics market is set to witness a valuation of $2.8B in 2022, and further expand at a CAGR of 9.3% to reach $6.8B by the year 2032.
Based on the Donepezil market share we can estimate that the total number of AD patients receiving drug’s treatment is about 2M in the US alone. In case we will perform our test once a month for each treated AD patient, we can estimate a total potential of over 24M annual tests in the US alone. The cost of EEG test in the US is about $100. Assuming we will charge additional $100 for our test (total price of $200 per test) we are talking about a potential of about $4.8 Billion in the US alone, and three times higher globally.
A POC study was completed.